Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Although fingolimod is registered in Europe for treatment of relapsing-remitting multiple sclerosis (RRMS) if earlier disease modifying therapy (DMT) has failed, no data regarding its efficacy in this patient group are available. This observational cohort study of the NeuroTransData network includes...

Descripción completa

Detalles Bibliográficos
Autores principales: Braune, Stefan, Lang, M., Bergmann, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751192/
https://www.ncbi.nlm.nih.gov/pubmed/26645389
http://dx.doi.org/10.1007/s00415-015-7970-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751192/
https://www.ncbi.nlm.nih.gov/pubmed/26645389
http://dx.doi.org/10.1007/s00415-015-7970-6

Ejemplares similares